AJANTPHARM

Ajanta Pharma Share Price

₹2,941.50 +7.55 (0.26%)

21 Nov, 2024 14:38

SIP TrendupStart SIP in AJANTPHARM

Start SIP

Performance

  • Low
  • ₹2,902
  • High
  • ₹2,966
  • 52 Week Low
  • ₹1,850
  • 52 Week High
  • ₹3,485
  • Open Price₹2,934
  • Previous Close₹2,934
  • Volume42,564

Investment Returns

  • Over 1 Month -8.09%
  • Over 3 Month -0.6%
  • Over 6 Month + 22.79%
  • Over 1 Year + 49.15%
SIP Lightning

Smart Investing Starts Here Start SIP with Ajanta Pharma for Steady Growth!

Invest Now

Ajanta Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 42
  • PEG Ratio
  • 1.3
  • Market Cap Cr
  • 36,743
  • P/B Ratio
  • 10.3
  • Average True Range
  • 113.84
  • EPS
  • 70.05
  • Dividend Yield
  • 1.8
  • MACD Signal
  • -69.93
  • RSI
  • 44.49
  • MFI
  • 58.55

Ajanta Pharma Financials

Ajanta Pharma Technicals

EMA & SMA

Current Price
₹2,941.50
+ 7.55 (0.26%)
pointer
  • stock-down_img
  • Bullish Moving Average 10
  • stock-up_img
  • Bearish Moving Average 6
  • 20 Day
  • ₹2,977.07
  • 50 Day
  • ₹3,031.56
  • 100 Day
  • ₹2,917.23
  • 200 Day
  • ₹2,649.90

Resistance and Support

2926.38 Pivot Speed
  • R3 3,057.22
  • R2 3,011.08
  • R1 2,972.52
  • S1 2,887.82
  • S2 2,841.68
  • S3 2,803.12

What's your outlook on Ajanta Pharma?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Ajanta Pharma is a specialty pharmaceutical company offering innovative, high-quality medicines across 30+ countries. With leadership in multiple therapeutic segments, Ajanta operates 7 state-of-the-art manufacturing facilities, supported by robust R&D capabilities and a strong global presence.

Ajanta Pharma has an operating revenue of Rs. 4,490.79 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 26% is great, ROE of 22% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 13% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 70 which is a FAIR score but needs to improve its earnings, a RS Rating of 69 which is FAIR indicating the recent price performance, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 36 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Ajanta Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-28 Quarterly Results
2024-07-30 Quarterly Results
2024-05-02 Audited Results & Buy Back of Shares
2024-01-31 Quarterly Results & 2nd Interim Dividend
2023-10-31 Quarterly Results
Date Purpose Remarks
2024-11-06 INTERIM Rs.28.00 per share(1400%)First Interim Dividend
2024-02-08 INTERIM Rs.26.00 per share(1300%)Second Interim Dividend
2023-08-04 SPECIAL Rs.15.00 per share(750%)Special Dividend
2023-08-04 INTERIM Rs.10.00 per share(500%)First Interim Dividend
2022-11-14 INTERIM Rs.7.00 per share(350%)Interim Dividend
Date Purpose Remarks
2022-06-23 Bonus Rs.0.00 issue in the ratio of 1:2 of Rs. 2/-.

Ajanta Pharma F&O

Ajanta Pharma Shareholding Pattern

66.26%
14.93%
1.57%
9.11%
0%
6.71%
1.42%

About Ajanta Pharma

  • NSE Symbol
  • AJANTPHARM
  • BSE Symbol
  • 532331
  • Managing Director
  • Mr. Yogesh M Agrawal
  • ISIN
  • INE031B01049

Similar Stocks to Ajanta Pharma

Ajanta Pharma FAQs

Ajanta Pharma share price is ₹2,941 As on 21 November, 2024 | 14:24

The Market Cap of Ajanta Pharma is ₹36742.9 Cr As on 21 November, 2024 | 14:24

The P/E ratio of Ajanta Pharma is 42 As on 21 November, 2024 | 14:24

The PB ratio of Ajanta Pharma is 10.3 As on 21 November, 2024 | 14:24

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23